全文获取类型
收费全文 | 2740篇 |
免费 | 139篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 61篇 |
妇产科学 | 75篇 |
基础医学 | 283篇 |
口腔科学 | 80篇 |
临床医学 | 185篇 |
内科学 | 513篇 |
皮肤病学 | 34篇 |
神经病学 | 128篇 |
特种医学 | 99篇 |
外科学 | 528篇 |
综合类 | 70篇 |
一般理论 | 4篇 |
预防医学 | 238篇 |
眼科学 | 85篇 |
药学 | 200篇 |
中国医学 | 11篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 36篇 |
2022年 | 88篇 |
2021年 | 95篇 |
2020年 | 65篇 |
2019年 | 84篇 |
2018年 | 101篇 |
2017年 | 69篇 |
2016年 | 69篇 |
2015年 | 76篇 |
2014年 | 101篇 |
2013年 | 130篇 |
2012年 | 209篇 |
2011年 | 236篇 |
2010年 | 130篇 |
2009年 | 106篇 |
2008年 | 167篇 |
2007年 | 185篇 |
2006年 | 152篇 |
2005年 | 168篇 |
2004年 | 123篇 |
2003年 | 130篇 |
2002年 | 91篇 |
2001年 | 19篇 |
2000年 | 11篇 |
1999年 | 12篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1996年 | 15篇 |
1995年 | 21篇 |
1994年 | 14篇 |
1993年 | 12篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1987年 | 16篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1980年 | 10篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1973年 | 5篇 |
1972年 | 6篇 |
1971年 | 8篇 |
排序方式: 共有2897条查询结果,搜索用时 15 毫秒
21.
22.
23.
Brock Kingstad-Bakke Woojong Lee Shaswath S. Chandrasekar David J. Gasper Cristhian Salas-Quinchucua Thomas Cleven Jeremy A. Sullivan Adel Talaat Jorge E. Osorio M. Suresh 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(20)
The first-generation COVID-19 vaccines have been effective in mitigating severe illness and hospitalization, but recurring waves of infections are associated with the emergence of SARS-CoV-2 variants that display progressive abilities to evade antibodies, leading to diminished vaccine effectiveness. The lack of clarity on the extent to which vaccine-elicited mucosal or systemic memory T cells protect against such antibody-evasive SARS-CoV-2 variants remains a critical knowledge gap in our quest for broadly protective vaccines. Using adjuvanted spike protein–based vaccines that elicit potent T cell responses, we assessed whether systemic or lung-resident CD4 and CD8 T cells protected against SARS-CoV-2 variants in the presence or absence of virus-neutralizing antibodies. We found that 1) mucosal or parenteral immunization led to effective viral control and protected against lung pathology with or without neutralizing antibodies, 2) protection afforded by mucosal memory CD8 T cells was largely redundant in the presence of antibodies that effectively neutralized the challenge virus, and 3) “unhelped” mucosal memory CD8 T cells provided no protection against the homologous SARS-CoV-2 without CD4 T cells and neutralizing antibodies. Significantly, however, in the absence of detectable virus-neutralizing antibodies, systemic or lung-resident memory CD4 and “helped” CD8 T cells provided effective protection against the relatively antibody-resistant B1.351 (β) variant, without lung immunopathology. Thus, induction of systemic and mucosal memory T cells directed against conserved epitopes might be an effective strategy to protect against SARS-CoV-2 variants that evade neutralizing antibodies. Mechanistic insights from this work have significant implications in the development of T cell–targeted immunomodulation or broadly protective SARS-CoV-2 vaccines.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to exert devastating impacts on the human life, with >280 million infections and over 5.4 million deaths to date. Although there are millions of convalescent people with some measure of immunity and 8.8 billion doses of vaccine administered to date, further threats of widespread severe COVID-19 disease looms heavily as immunity induced by infection or the first-generation vaccines may not provide effective and durable protection, either due to waning immunity or due to poor antibody cross-reactivity to new variants (1–5).It is clear that virus-neutralizing antibodies provide the most effective protection to SARS-CoV-2, following vaccination or recovery from infection (6). However, T cell–based protection against SARS-CoV-2 has become a central focus because T cells recognize short amino acid sequences that can be conserved across viral variants (7–9). Indeed, T cells in convalescent COVID-19 patients have shown robust responses that are directed at multiple viral proteins, and depletion of these T cells delayed SARS-CoV-2 control in mice (10–12). These data suggest a protective role for T cells in COVID-19 infection. In effect, what constitutes an effective, an ineffective, or a perilous T cell response to SARS-CoV-2 in lungs remains poorly defined. Controlled studies in laboratory animals are of critical importance to elucidate the role and nature of T cells in lungs during SARS-CoV-2 virus infection and in protective immunity.Based on the differentiation state, anatomical localization and traffic patterns, memory T cells are classified into effector memory (TEM), central memory (TCM), and tissue-resident memory (TRM) (13, 14). There is accumulating evidence that airway/lung-resident TRMs, and not migratory memory T cells (TEMs) are critical for protective immunity to respiratory mucosal infections with viruses, such as influenza A virus (IAV) and respiratory syncytial virus (15–21). Development of TRMs from effector T cells in the respiratory tract requires local antigen recognition and exposure to critical factors, such as transforming growth factor (TGF)-β and interleukin (IL)-15 (15). Therefore, mucosal vaccines are more likely to elicit TRMs in lungs than parenteral vaccines (22, 23). A subset of effector T cells in airways of COVID-19 patients display TRM-like features (24), but the development of TRMs or their importance in protective immunity to reinfection are yet to be determined. Furthermore, all SARS-CoV-2 vaccines in use are administered parenterally and less likely to induce lung TRMs. While depletion of CD8 T cells compromised protection against COVID-19 in vaccinated rhesus macaques (25), the relative effectiveness of vaccine-induced systemic/migratory CD8 T cell memory vs. lung/airway TRMs in protective immunity to COVID-19 is yet to be defined.In this study, using the K18-hACE2 transgenic (tg) mouse model of SARS-CoV-2 infection, we have interrogated two key aspects of T cell immunity: 1) the requirements for lung-resident vs. migratory T cell memory in vaccine-induced immunity to SARS-CoV-2; and 2) the role of lung-resident memory CD4 vs. CD8 T cells in protection against viral variants in the presence or absence of virus-neutralizing antibodies. Studies of mucosal versus systemic T cell–based vaccine immunity using a subunit protein-based adjuvant system that elicits neutralizing antibodies and T cell immunity, demonstrated that: 1) both mucosal and parenteral vaccinations provide effective immunity to SARS-CoV-2 variants; 2) CD4 T cell–dependent immune mechanisms exert primacy in protection against homologous SARS-CoV-2 strain; and 3) the development of spike (S) protein-specific “unhelped” memory CD8 T cells in the respiratory mucosa are insufficient to protect against a lethal challenge with the homologous Washington (WA) strain of SARS-CoV-2. Unexpectedly, we found that systemic or mucosal lung-resident memory CD4 and “helped” CD8 T cells engendered effective immunity to the South African B1.351 β-variant in the apparent absence of detectable mucosal or circulating virus-neutralizing antibodies. Taken together, mechanistic insights from this study have advanced our understanding of viral pathogenesis and might drive rational development of next-generation broadly protective SARS-CoV-2 vaccines that induce humoral and T cell memory. 相似文献
24.
The influence of a single dose of aspirin on the pharmacokinetics of the synthetic progestogen norethindrone was studied in rabbits. It was found that neither the 24-hr plasma levels nor the pharmacokinetic parameters of norethindrone following intravenous dosing were significantly altered by aspirin. However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 ± 0.058 ng/ml × hr to 0.49 ± 0.046 ng/ml × hr (mean ± S.E) and the oral bioavailability was reduced from 56 ± 4.2% to 38 ± 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin. 相似文献
25.
26.
Adel Shahnam Robyn Sayer Unine Herbst Raghwa Sharma Won-hee Yoon Tim Dinihan Bo Gao 《Current oncology (Toronto, Ont.)》2022,29(6):4148
Growing teratoma syndrome (GTS) is rare and can mimic disease recurrence in patients with a history of immature teratoma. Benign hypermetabolic lymphadenopathy found on staging and surveillance computed tomography (CT) and positron emission tomography (PET) may lead to the presumption of metastatic malignancy. We report a case of a 38 year old with mixed mature and immature teratomas who developed new peritoneal masses after adjuvant chemotherapy despite a normalization of tumor markers. In addition to low FDG uptake observed in these peritoneal masses, a PET scan showed hypermetabolic lymphadenopathy and pulmonary and spleen lesions suggesting widespread metastases. Subsequent surgical resection confirmed a mixed pathology with GTS and sarcoidosis. We reviewed the current literature evidence of GTS and sarcoidosis as a benign cause of lymphadenopathy in cancer patients. We emphasize the importance of a tissue diagnosis before instituting therapy for presumed cancer recurrence to avoid potentially fatal diagnostic traps and management errors. A multiple disciplinary team approach is imperative in managing patients with suspected recurrent immature teratomas. 相似文献
27.
Hani Z. Asfour Nabil A. Alhakamy Osama A. A. Ahmed Usama A. Fahmy Shadab Md Mohamed A. El-Moselhy Waleed Y. Rizg Adel F. Alghaith Basma G. Eid Ashraf B. Abdel-Naim 《Drug delivery》2022,29(1):1892
The present study aimed to design and optimize, a nanoconjugate of gabapentin (GPN)-melittin (MLT) and to evaluate its healing activity in rat diabetic wounds. To explore the wound healing potency of GPN-MLT nanoconjugate, an in vivo study was carried out. Diabetic rats were subjected to excision wounds and received daily topical treatment with conventional formulations of GPN, MLT, GPN-MLT nanoconjugate and a marketed formula. The outcome of the in vivo study showed an expedited wound contraction in GPN-MLT-treated animals. This was confirmed histologically. The nanoconjugate formula exhibited antioxidant activities as evidenced by preventing malondialdehyde (MDA) accumulation and superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymatic exhaustion. Further, the nanoconjugate showed superior anti-inflammatory activity as it inhibited the expression of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). This is in addition to enhancement of proliferation as indicated by increased expression of transforming growth factor-β (TGF- β), vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor receptor-β (PDGFRB). Also, nanoconjugate enhanced hydroxyproline concentration and mRNA expression of collagen type 1 alpha 1 (Col 1A1). In conclusion, a GPN-MLT nanoconjugate was optimized with respect to particle size. Analysis of pharmacokinetic attributes showed the mean particle size of optimized nanoconjugate as 156.9 nm. The nanoconjugate exhibited potent wound healing activities in diabetic rats. This, at least partly, involve enhanced antioxidant, anti-inflammatory, proliferative and pro-collagen activities. This may help to develop novel formulae that could accelerate wound healing in diabetes. 相似文献
28.
Algimantas Budrikis Mindaugas Jievaltas Sami Al Assaad Sarunas Kinduris 《Journal of cardiothoracic surgery》2012,7(1):1-4
A 37-year-old man with end-stage idiopathic dilated cardiomyopathy underwent an orthotopic heart transplant followed by a reoperation with mitral annuloplasty for severe mitral regurgitation. Shortly thereafter, he developed severe tricuspid regurgitation and severe recurrent mitral regurgitation due to annuloplasty ring dehiscence. The dehisced annuloplasty ring was refixated, followed by tricuspid annuloplasty through a right anterolateral thoracotomy. After four years of follow-up, there are no signs of recurrent mitral or tricupid regurgitation and the patient remains in NYHA class II. Pushing the envelope on conventional surgical procedures in marginal donor hearts (both before and after transplantation) may not only improve the patient??s functional status and reduce the need for retransplantation, but it may ultimately alleviate the chronic shortage of donor hearts. 相似文献
29.
30.
Pham Daniel Polgar Beata Toth Tunde Jungling Adel Kovacs Norbert Balas Istvan Pal Endre Szabo Dora Fulop Balazs Daniel Reglodi Dora Szanto Zalan Herczeg Robert Gyenesei Attila Tamas Andrea 《Age (Dordrecht, Netherlands)》2022,44(2):785-803
GeroScience - The neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) have been shown in numerous in vitro and in vivo models of Parkinson’s disease (PD)... 相似文献